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Klotho is an anti-aging gene whose expression is regulated
by many stimuli. Here we examined the transcriptional
regulation of the klotho gene by peroxisome
proliferator-activated receptor-c (PPAR-c). The PPAR-c
agonists thiazolidinediones increased both klotho mRNA
and protein expression in HEK293 cells and several renal
epithelial cell lines. The induction was blocked by PPAR-c
antagonists or small-interfering RNA-mediated gene
silencing of PPAR-c, suggesting a PPAR-c-dependent
mechanism. Chromatin immuno-precipitation and gel shift
assays found a noncanonical PPAR-responsive element
within the 50-flanking region of the human klotho gene
with promoter–reporter assays further confirming
transcriptional functionality. Moreover, thiazolidinediones
or adenovirus-mediated overexpression of PPAR-c
increased klotho expression in mouse kidneys while renal
klotho expression was attenuated in mice treated with
PPAR-c antagonists. These results demonstrate that
klotho is a target gene of PPAR-c.
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The klotho gene encodes a type I transmembrane protein that
shares homology with b-glucosidase. Klotho deficiency in
mice results in a phenotype resembling human aging,
including arteriosclerosis, neural degeneration, defective
hearing, skin and gonadal atrophy, ectopic calcification in
various soft tissue, pulmonary emphysema, and greatly
shortened lifespan.1 The klotho gene is predominantly
expressed in the kidney and, to a lesser extent, in the brain
and reproductive and endocrine organs. The expression of
the klotho gene is regulated in response to various
physiological and pathological conditions such as thyroid
hormone, oxidative stress, long-term hypertension, chronic
renal failure,2 and so on.
To date, little has been known about the transcriptional
mechanisms underlying the regulated expression of the klotho
gene. Peroxisome proliferator-activated receptors (PPARs)
are a family of ligand-activated nuclear hormone receptor
and transcription factors.3,4 Among the three isoforms a, b/d,
and g, PPAR-g is predominantly expressed in adipose tissues
and, to a lesser extent, in other tissues including kidneys.5,6
PPAR-g is activated by various natural and synthetic ligands
and plays important roles in adipogenesis 7 and insulin
sensitivity.8 An earlier study showed that troglitazone, an
insulin sensitizer and agonist for PPAR-g, augmented the
renal klotho mRNA expression in OLETF (Otsuka Long-
Evans Tokushima Fatty) rats, which exhibit pathophysio-
logical changes that resemble metabolic syndrome in human,
including hypertension, obesity, severe hyperglycemia, and
hypertriglyceridemia.9 It has also been recently described that
klotho promotes adipocyte differentiation in cultured pre-
adipocytes10 and that, in transgenic mice, overexpression of
klotho slows the aging process through induction of insulin
resistance. However, the role of PPAR-g in the regulation of
the klotho gene expression remains unknown. Therefore, this
study was performed to characterize the specific role of
PPAR-g in the induction of the klotho gene both in vitro and
in vivo.
RESULTS
Thiazolidinediones increased expression of klotho
mRNA in dose- and time-dependent manners
To determine the effect of PPAR-g on the expression of
klotho gene, we treated 293 cells with PPAR-g agonists
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troglitazone and ciglitazone, both being thiazolidinediones
(TZDs), at various concentrations for different time periods.
Klotho mRNA level was measured by quantitative reverse-
transcriptase-PCR (qRT-PCR). As shown in Figure 1, both
troglitazone and ciglitazone significantly increased the
mRNA expression of klotho gene in 293 cells in a time-
and dose-dependent manner. To ascertain whether TZDs also
induce klotho gene expression in differentiated renal tubular
epithelial cells, we further examined the effect of troglitazone
in IMCD (inner medullary collecting ducts cells), MCT
(proximal tubular epithelial cells),11 and MDCK (distal
tubule cells)12,13 cell lines. Northern analysis confirmed that
klotho gene was expressed to different extent in all the three
cell lines tested, and the expression was similarly induced by
troglitazone (Figure 2b).
Thiazolidinedione induction of klotho expression was
dependent on PPAR-c activation
To examine whether the TZD-induced expression of klotho
was mediated by PPAR-g activation, cells were pretreated
with a selective PPAR-g antagonist GW9662 (20 mM for 1 h)
prior to the incubation with troglitazone. Both qRT-PCR and
northern blotting demonstrated that GW9662 blocked the
troglitazone-induced increase of klotho mRNA (Figure 2a
and b). Similarly, bisphenol-A diglycidyl ether (BADGE),
another PPAR-g antagonist, also reduced the induction of
klotho expression by troglitazone (Figure 2a, lower panel). To
further confirm the role of endogenous PPAR-g on the
expression of klotho mRNA, the cells were transfected with
PPAR-g-specific short interfering RNA (siRNA) or green
fluorescence protein (GFP)-siRNA as a control. As shown in
Figure 2c, the expression level of the endogenous PPAR-g was
reduced by approximately 90% compared with the control
siRNA-transfected cells. Knockdown of PPAR-g abrogated
the trogilatazone-induced expression of klotho. Taken
together, these results suggested that TZD-induced klotho
expression was dependent on the activation of endogenous
PPAR-g.
Characterization of the PPRE within the 50-flanking
region of human klotho gene
Sequence analysis of the 50-flanking region of human klotho
gene revealed no typical binding site for PPARs. However,
two noncanonical PPAR-responsive element (PPRE) motifs
were found, one at –3698 bp (GAACTCCTGACCT) and the
other at 2760 bp (ACTGGATGAAGGA) upstream of the
ATG start codon. The binding activities of these regions to
PPAR-g were examined by chromatin immunoprecipitation
(ChIP) assay, which showed that the region harboring the
distal PPRE could be immunoprecipitated by PPAR-g
antibody but not the control IgG (Figure 3a), indicating
that PPAR-g was able to bind to this region of the klotho
gene in 293 cells. To further examine whether the
noncanonical PPRE (–3698) motif binds PPAR-g and
whether the binding was affected by the PPAR-g ligand, we
performed EMSA (electrophoretic mobility shift assay) with
the oligonucleotide probe. The results showed that the probe
containing the region between 3698 and 3686 bp was
shifted by the nuclear proteins. The DNA binding was
increased by the troglitazone treatment and abolished by the
unlabeled probes (Figure 3b). However, the oligonucleotide
probe containing the PPRE-2 (–2760/2746 bp) was not
shifted by the nuclear extract (data no showed). In addition,
the PPAR-g antibody resulted in a super-shifted band (Figure
3b). Thus, these results indicated that PPAR-g may directly
bind to the noncanonical PPRE to activate the klotho gene.
To further validate the transcriptional functionality of this
noncanonical PPRE, we transfected the luciferase reporter-
driven by 2KL-PPRE into human embryonic kidney
(HEK) 293 (HEK293 cells; 293 cell line was used because it
has a better transfection efficiency). As shown in Figure 3c,
rosiglitazone increased the transcriptional activity of the
reporter and the induced activity was abolished in the
presence of GW9662. These results indicated that PPAR-g
activated klotho expression through a functional cis-element
within the klotho gene.
Effects of TZDs and PPAR-c antagonist on the expression
of klotho gene in vivo
To determine whether klotho is a target gene of PPAR-g
in vivo, we have treated C57BL/6 mice with or without
troglitazone (200 mg/kg/day) for 3 days and measured the
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Figure 1 | TZDs increased klotho expression in a dose- and
time-dependent manner. HEK293 cells were treated with control
medium, the solvent DMSO, and the TZDs troglitazone (a) or
ciglitazone (b) for the indicated time periods. Relative mRNA level
of klotho gene was determined by using qRT-PCR and, after
normalization with b-actin, expressed as the fold induction in
relation to the control. Data represent means±s.e.m. of three
independent experiments. *Po0.05, **Po0.01 vs control.
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klotho expression at both mRNA and protein levels. The
qRT-PCR and northern blotting (Figure 4a) showed that the
klotho mRNA level was significantly increased in the kidney
of troglitazone-treated mice compared with the control
group. Similarly, the protein level of klotho was also increased
by troglitazone (Figure 4b). To examine whether different
PPAR-g agonist elicited the same effect in vivo, mice were
also treated with rosiglitazone. The results showed that
rosiglitazone at a lower dose (20 mg/kg/day) elicited a
similar induction of klotho gene expression in the kidneys.
Importantly, treatment with BADGE, a PPAR-g antagonist,
significantly reduced the TZD-induced expression, suggesting
that PPAR-g activation is required for the klotho induction
by TZD in vivo (Figure 4c).
Adenovirus-mediated overexpression of PPAR-c activated
the expression of klotho gene in vivo
To further investigate whether PPAR-g activation is sufficient
to induce the klotho expression in vivo, a constitutively active
PPAR-g was adenovirally infected into the mouse kidney. As
shown by qRT-PCR and western blotting, Ad-PPAR-g but
not Ad-GFP infection achieved the overexpression of PPAR-g
in mouse kidneys, which subsequently resulted in a marked
increase in klotho at mRNA and protein levels. The
immunohistochemical studies also demonstrated that intra-
renal infection of Ad-PPRA-g induced overexpresion of
PPAR-g, which was stained positive in the nuclei for the HA
antibody. Klotho expression was clearly induced and
predominantly shown as membrane-associated staining
(Figure 5c). The sections were stained negative when the
primary antibody was omitted (figure not shown). Therefore,
the results suggest that PPAR-g activation is sufficient to
induce the klotho expression in situ.
DISCUSSION
In the present study, we have established a novel transcrip-
tional mechanism that controls the expression of klotho, an
important anti-aging hormone, by showing that klotho is a
target gene of PPAR-g in the cultured kidney cells as well as in
mouse kidneys in vivo. This conclusion is supported by both
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Figure 2 | TZD-induced klotho expression is dependent on PPAR-c activation. (a) HEK293 or renal cell lines were treated with or without
GW9662 (20mM) or BADGE (20mM) for 1 h and exposed to DMSO or troglitazone (50 mM) for 24 h. Total RNA was extracted and subjected
to northern blotting (the upper panel) and qRT-PCR (the lower panel). (b) Northern analysis of klotho gene expression in IMCD, MCT,
or MDCK cell lines. The bar graph represents the results of scanned densities of three northern blotting experiments using the NIH Image J
after normalization with b-actin. (c) HEK293 cells were transfected with siRNA specific for PPAR-g or GFP (40 nM) for 48 h before the
exposure to troglitazone or DMSO. Relative mRNA levels of PPAR-g and klotho were determined by using qRT-PCR. *Po0.05; **Po0.01.
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the loss-of-function and the gain-of-function approaches:
TZD induction of klotho was attenuated in the presence of
specific antagonists GW9662 and BADGE both in vitro and in
vivo or the knockdown of endogenous PPAR-g by using the
specific siRNA; conversely, the pharmacological TZD agonists
and the ligand-independent constitutive activation resulted
in the induction of klotho. Moreover, we have identified a
functional noncanonical PPRE motif within the 50-flanking
region of the klotho gene that is recognized by PPAR-g and
may mediate the inductive effect of PPAR-g.
A previous study described that administration of
troglitazone for 10 weeks significantly reduced systolic blood
pressure, plasma glucose, and triglyceride levels, while
augmenting endothelium-dependent aortic relaxation and
renal klotho mRNA expression in OLETF rats.14 However, it
remained unclear whether the augmented expression of
klotho mRNA was due to a direct effect of PPAR-g activation
or an indirect effect secondary to the improved metabolism.
A recent report showed that in 3T3-L1 preadipocytes a TZD
agonist, pioglitazone, temporarily increased the klotho
mRNA expression and that recombinant klotho protein
accelerated adipocyte differentiation, suggesting a link
between klotho and adipogenesis.10 Here, our study has
provided the first evidence for a specific and direct role of
PPAR-g in the transcriptional control of klotho gene
expression.
PPAR-g is a key transcription factor controlling adipo-
genesis and insulin sensitivity. PPAR-g dimerizes with
retinoid X receptor and activates the gene expression by
binding to the cognate PPRE within the regulatory region of
the target genes. Although there has been no apparent
consensus PPRE found within the regulatory region of the
klotho gene, noncanonical motifs for PPAR-g have been
identified in many PPAR-g target genes.15,16 They are often
located at a distal region upstream of the transcription
initiative site.17 By using ChIP, gel shift, and supershift assays,
we have identified a novel PPRE motif that can be recognized
by PPAR-g. Moreover, the reporter assay showed that the
noncanonical PPRE is functionally activated by rosiglitazone
and the activation is abolished by the PPAR-g antagonist
GW0742. These results, taken together, support the concept
that klotho is a target gene of PPAR-g. However, the lack of
larger segments of the 50-flanking region upstream of
the human and mouse klotho genes limits understanding
of the interactive role of this motif with other regulatory
elements.
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Figure 3 | PPAR-c bound to the PPRE within the 50-flanking region of klotho gene. (a) The diagram depicts the putative PPRE motifs
located in the 50-flanking region of the human klotho gene. HEK293 cells were coinfected with Ad-PPAR-g and Ad-tTA for 24 h. ChIP assays
were performed with the antibodies against PPAR-g or IgG as control. The immunoprecipitates and the positive input control were
amplified with the use of specific primer sets spanning the DNA segments containing the putative PPRE-1 and PPRE-2. (b) EMSA was
performed by incubating the nuclear extracts from the control or troglitazone-treated cells with the 32P-ATP-labeled probe corresponding
to the consensus PPRE (AOX) or the klotho PPRE-1 motif (KL). Cold competition assays were done by adding the unlabeled specific (cold KL)
or nonspecific (NS) probe to the binding reactions. Supershift assays were done by adding the control IgG or the PPAR-g antibody.
Data shown are representative of at least three independent experiments. Arrow indicates the shifted DNA–protein complex. (c) HEK293
cells transfected with the KL-PPRE-Luc and the b-gal plasmids were treated with DMSO (control) or rosiglitazone (RO, 20 mM) with or
without GW9662 (GW, 20mM). Luciferease activity was normalized to b-gal activity and expressed as fold induction compared with control.
Data are mean±s.e.m. of three independent experiments. **Po0.01; ***Po0.01.
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Figure 4 | Troglitazone increases the expression of klotho in mouse kidneys. (a) Total RNA was extracted from the kidneys from the
control C57bl mice or those treated with troglitazone for 3 days. Expression of klotho mRNA was detected with northern blotting and
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Figure 5 | Adenovirus-mediated overexpression of PPAR-c increased the expression of klotho in mouse kidneys. Mice were
intra-renally injected with Ad-GFP or Ad-PPAR-g, together with Ad-tTA. Total RNA and protein were extracted 48 h later and subjected
to qRT-PCR for the detection of PPAR-g and klotho mRNA (a), or western blotting for klotho, a-tubulin, or the HA tagged to the
adenovirally expressed PPAR-g (b). **Po0.01 vs control. (c) Immunohistochemical staining shows that intra-renal overexpression of PPAR-g,
as shown by the HA-antibody staining, resulted in an increased expression of klotho protein in situ. Bar¼ 50 mM.
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The klotho gene encodes a single-pass transmembrane
protein that is detectable in a limited number of tissues
including kidney and brain. In kidney, klotho is expressed at
a high level in convoluted tubules as well as in other tubular
epithelia such as inner medullary collecting duct cells.1,18
Besides using HEK293, we also examined the regulation of
klotho by PPAR-g in several other renal cell lines including
MDCK, MCT, and IMCD. These cell lines are known
to exhibit many features for distal tubules, proximal
tubules, and inner medullary collecting ducts, respec-
tively.10–13 In this study, we found that TZDs induce klotho
expression both in HEK293 cells and, more importantly,
several differentiated renal tissues across a number of species,
implying that the PPAR-g induction of renal klotho
represents an evolutionarily conserved mechanism and may
have an important physiological significance. It has been
reported that gene expression of klotho was reduced in
patients with chronic renal failure.2 The downregulation
of the klotho gene in the kidney could exacerbate ischemic
renal failure and of the renal damage induced by angio-
tensin II.19,20 Moreover, a recent study demonstrated that
klotho may serve as a potential renoprotective humoral
factor by reducing mitochondrial oxidative stress.21 Up
to one-third diabetic patients suffer end-stage renal failure
due to diabetic nephropathies. Clinical studies have demon-
strated that TZDs ameliorate diabetic nephropathy and
many of the favorable effects of TZDs occur through both
PPAR-g-dependent and -independent mechanisms.22–24
Given our results that klotho is a renal target of PPAR-g,
it is suggested that the upregulation of klotho expression
by PPAR-g may contribute to the protective effects of
TZDs in renal complications of the type II diabetes. These
findings may have important pathophysiological significance.
Intriguingly, an interaction between klotho and insulin
resistance has been recently uncovered. Koro-o and collea-
gues found that klotho functions as a humoral factor that
signals suppression of intracellular insulin/IGF1 signaling,
which may contribute to its anti-aging properties.25,26 Since
PPAR-g is an important therapeutic target for the treatment
of insulin resistance and type II diabetes, the functional
role of klotho regulation by PPAR-g warrants further
investigation.
In conclusion, our study demonstrates a novel transcrip-
tional mechanism by which the TZD insulin sensitizers
regulate the klotho expression. These results suggest an
important link between PPAR-g and klotho, the renal-
derived hormone.
MATERIALS AND METHODS
Cells and reagents
Human embryonic kidney 293, mouse proximal tubular cells
(MCT), Madin–Darby canine renal distal tubular cells (MDCK),
and inner medullary collecting ducts cells (IMCD) (ATCC, Rock-
ville, MD, USA) were grown in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum (FBS). Troglitazone (Parke-Davis
Pharmaceuticals, Detroit, MI, USA), ciglitazone, rosiglitazone,
BADGE, and GW9662 (Cayman Chemical, Ann Arbor, MI, USA)
were dissolved in dimethyl sulfoxide (DMSO).
RNA analyses
Total RNA was isolated from HEK293 cells or mouse kidneys using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). For qRT-PCR,
cDNA was generated from 2 mg RNA by using Superscript II
reverse transcriptase and oligo-dT primer (Invitrogen). PCR
reactions were performed with the use of specific primers
(Table 1) on Opticon continuous fluorescence detection system
(MJ Research Inc., Waltham, MA, USA) with SYBR green
fluorescence (Molecular Probes, Eugene, OR, USA). Gene expression
was quantified by using the comparative CT method, normalized to
b-actin and expressed as fold induction of control. For northern
blotting, 20 mg of RNA for each sample was separated on a
1.2% agarose-formaldehyde gel, transferred to nitrocellulose, and
hybridized with a-32P-dCTP-labeled cDNA probes for klotho or
b-actin.27
Western blotting
Protein samples were extracted from mouse kidneys as previously
described, with modifications.28 Briefly, mice were killed and the
kidneys were homogenized in the homogenizing buffer (0.25 M
sucrose, 2 mM EDTA (ethylenediaminetetraacetic acid), 10 mM
EGTA (ethyleneglycol tetraacetate), 10 mM 2-mercaptoethanol, and
20 mM Tris-HCl, pH7.5). The homogenates were centrifuged at
12,000 r.p.m. for 10 min at 41C, and the supernatant was centrifuged
at 100,000 r.p.m. for 3 h at 41C. The pellets were resuspended in the
homogenizing buffer, supplemental with 1% Triton X-100 and
4% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonate). Protein samples were separated on 10% SDS-PAGE
Table 1 | Sequences for primers and probes used
Gene Accession no. Sequences
Primers for PCR
Human klotho NM_004795 50-gcccacatactggatggtatcaa-30
50-actgcactcagtacacacggtga-30
Mouse klotho NM_013823 50-acaaagaagtggccgagaga-30
50-cctgactgggagagttgagc-30
Human PPAR-g NM_138712 50-tcatggcaattgaatgtcgt-30
50-ccaacagcttctccttctcg-30
b-Actin EF607093 50-atctggcaccacaccttc-30
50-agccaggtccagacgca-30
Primers for ChIP assay
Klotho PPRE-1 50-gccaccatgttggtgaattt-30
50-tcacacctgtaatcccagca-30
Klotho PPRE-2 50-agtgcatctcctgctccatt-30
50-cttgctgtgctttgaacagg-30
Probes for EMSAa
Consensus PPRE
(Aco oxidase)
50-ggggaccaggacaaaggtcacgttc
gggagct-30
Klotho PPRE-1 50-ctcgaactcctgaccttag-30
Klotho PPRE-2 50-ggcactggatgaaggaatg-30
siRNAa
GFP-siRNA 50-ggcuacguccaggagcgcacc-30
PPAR-g-siRNA 50-gagugggaguggucuuccauu-30
ChIP, chromatin immunoprecipitation, EMSA, electrophoretic mobility shift assay;
GFP, green fluorescence protein; PPAR-g, peroxisome proliferator-activated
receptor-g; PPRE, PPAR-responsive element; siRNA, small interfering RNA.
aComplementary sequences are omitted.
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(sodium dodecil sulfate-polyacrylamide gel electrophoresis),
transferred to nitrocellulose and probed by using a rat monoclonal
antibody against klotho (1:1000) or rabbit antibody against
a-tubulin, followed by detection with horseradish peroxidase-
labeled secondary antibodies and the ECL chemiluminescence kit
(Amersham, Piscataway, NJ, USA).29
RNA interference
Short interfering RNA specific for GFP, human PPAR-g, or human
klotho30 were synthesized (see Table 1 for the sequences), annealed,
and transfected into HEK293 cells using Lipofectamine 2000
(Invitrogen) as previously described.31
Chromatin immunoprecipitation and electrophoretic
mobility shift assays
Cells were coinfected with Ad-PPAR-g, which expresses a mouse
PPAR-g1 fused to a minimal VP16 transactivation domain and
tagged with an HA-epitope, and Ad-tTA that encodes a tetracycline-
responsive transactivator in the presence or absence of tetracycline
(0.1 mg/ml) for 24 h, as previously described.27 For ChIP assays, cells
were crosslinked with formaldehyde, and sonicated and immuno-
precipitated with the antibody against PPAR-g or control IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The eluted DNA and
the input control were detected by PCR amplification (30 cycles)
using the specific primer sets spanning the putative PPRE within the
50-flanking region of the human klotho gene (0ENSG00000133116,
see Table 1 for sequences).32 For EMSA, 5 mg of the nuclear extracts
were incubated with the [g-32P]ATP-labeled double-strand oligo-
nucleotides and poly (dI-dC) for 30 min on ice, and then resolved
on a 4% polyacrylamide gel. The unlabeled probe was included
100 M in excess in cold competition assays.33
Promoter–reporter assay
To construct the KL-PPRE-luciferase reporter plasmid, we synthe-
sized complementary oligonucleotides containing two repeats of the
putative klotho PPRE (the motifs are in italic) (50-ATAGGTACCG
TCTCGAACTCCTGACCTTAGGTGGTCTCGAGTCTCGAACTCTGA
CCTTAGGTGGTCTAAGCTTGG-30) and flanking sites for KpnI and
HindIII. The double strands were annealed and subcloned to pGL3-
Enhancer (Promega, Madison, WI, USA). The KL-PPRE-Luc
plasmid (1 mg/well) was transfected together with the b-galacto-
sidase expression plasmid into subconfluent 293 cells with the use
of Lipofectamine 2000 (Invitrogen). Twenty-four hours later, the
cells were treated with DMSO, rosiglitazone, or GW9662. Cell lysates
were harvested 24 h later to measure luciferase and b-galactosidase
activities.
Animal experiments
Animal protocols were approved by the Peking University Health
Science Center, complying with the Guideline for Care and Use of
Laboratory Animals. C57BL/6 mice weighting 25–30 g were given
troglitazone (200 mg/kg/day), rosiglitazone (20 mg/kg/day), or
BADGE (10 mg/kg/day) by oral gavage. Alternatively, intra-renal
adenoviral infection was performed under pentobarbital anesthetiza-
tion. Ad-PPAR-g or Ad-GFP, together with Ad-tTA was injected into
kidney at 1 109 PFU. Three days after the troglitazone treatment or
the adenoviral infection, the mice were killed and the kidneys were
immediately excised to extract the RNA and protein, or frozen-
embedded in optimum cutting temperature compound for immuno-
histochemical study.
Immunohistochemistry
Cryostat sections (6 mm) of frozen kidneys were fixed in 4%
paraformaldehyde. Endogenous peroxidase activity was blocked
with 0.3% hydrogen peroxide. Sections were reacted with the
primary antibodies against klotho (rat anti-mouse klotho mono-
clonal antibody; R&D, Minneapolis, MN, USA) or HA (mouse anti-
HA monoclonal antibody; Sigma-Aldrich, St Louis, MO, USA).
After washing, the sections were incubated with secondary
antibodies (biotinylated rabbit anti-rat or anti-mouse IgG), and
then with avidin–biotin–peroxidase complex (Vector Laboratories,
Burlingame, CA, USA). Sections were visualized with diaminoben-
zidine substrate and counterstained with hematoxylin.34
Statistical analysis
Statistical analyses were performed by one-way ANOVA (analysis
of variance) or Student t-test. Data are expressed as mean±s.e.m.
The P-values less than 0.05 were considered statistically significant.
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